Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N2O2.C14H21ClN2O2.2H2O |
Molecular Weight | 629.187 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.CCN(CC)CCNC(=O)COC1=CC=C(Cl)C=C1.CCCCC2C(=O)N(N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=FNOZOEQGHOYGSF-UHFFFAOYSA-N
InChI=1S/C19H20N2O2.C14H21ClN2O2.2H2O/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;1-3-17(4-2)10-9-16-14(18)11-19-13-7-5-12(15)6-8-13;;/h4-13,17H,2-3,14H2,1H3;5-8H,3-4,9-11H2,1-2H3,(H,16,18);2*1H2
Clofezone (Perclusone), an analgesic and anti-inflammatory agent, is a drug that was used to treat joint and muscular pain, mostly in rheumatic diseases. Clofezone is a compound preparation of phenylbutazone and clofexamide. Tolerance of Perclusone was very good, no side-effects were observed.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/153679
The effectiveness and acceptability of clofezone (Perclusone) were compared with those of diclofenac in a placebo-controlled, double-blind, cross-over trial on a group of 29 out-patients suffering from osteoarthrosis of the knee or hip. Clofezone was given at a daily dosage of 1200 mg during the first week and 600 mg during the second week; the corresponding dosages of diclofenac were 150 mg and 75 mg.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AA05
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
||
|
WHO-VATC |
QM02AA03
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
||
|
WHO-ATC |
M01AA05
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
||
|
WHO-ATC |
M02AA03
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
183877
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
C77346
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
DTXSID50208852
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
300000040303
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
8768
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
4335
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
2274
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
60104-29-2
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
6443874
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
CLOFEZONE
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
C073326
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY | |||
|
TPT3MH65LD
Created by
admin on Fri Dec 15 16:12:39 GMT 2023 , Edited by admin on Fri Dec 15 16:12:39 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD